474708-98-0

Basic information

• Product Name: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE
• Synonyms: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE;IMidazo[1,2-a]pyridine-3-carbonitrile, 6-broMo-;6-bromoimidazo[1,2-a]pyrazine-3-carbonitrile
• CAS NO: 474708-98-0
• Molecular Formula: C₈H₄BrN₃
• Molecular Weight: 222.045
• Mol File: 474708-98-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.71±0.1 g/cm3(Predicted)
• PKA: 0.86±0.50(Predicted)
• CAS DataBase Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(474708-98-0)
• EPA Substance Registry System: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(474708-98-0)

Safety Data

• Hazardous Substances Data: 474708-98-0(Hazardous Substances Data)

Usage

General Description

6-Bromo-imidazo[1,2-a]pyridine-3-carbonitrile is a chemical compound with the molecular formula C7H3BrN4. It is a heterocyclic compound with an imidazole ring fused to a pyridine ring and a nitrile functional group at position 3. 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE is used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has been studied for its potential biological activities and is of interest in medicinal chemistry research. Its unique structure and reactivity make it a valuable tool for the development of new chemical compounds with diverse applications.

Upstream product

• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 590-17-0 cyanomethyl bromide 
• 138888-98-9 N’-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 106-96-7 propargyl bromide 
• 107-14-2 chloroacetonitrile 
• 944896-42-8 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid 
• 2044706-79-6 6-bromoimidazo[1,2-a]pyridine-3-carboxamide 

Downstream Products

• 1004550-16-6 6-vinylimidazo[1,2-a]pyridine-3-carbonitrile 
• 1276110-12-3 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1276110-04-3 N-(5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-08-7 N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-30-5 2,4-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-33-8 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1276110-36-1 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 944896-42-8 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid 
• 1989745-33-6 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-3-carbonitrile 

Relevant articles and documents

AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are an aromatic heterocyclic compound, an intermediate thereof, a preparation method therefor, and a pharmaceutical composition and use thereof. The aromatic heterocyclic compound of the present invention is a new ALK5 inhibitor, and is used for treating and/or preventing various ALK5-mediated diseases.

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

Convenient two-step one-pot synthesis of 3-substituted imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines

Abstract: A convenient and novel two-step one-pot method for the synthesis of 3-substituted imidazo[1,2-a]pyridines and 3-substituted imidazo[1,2-b]pyridazines was developed through the reaction of heterocyclic amines and N,?N-dimethylformamide dimethyl a